ProCE Banner Activity

It’s Back Again: New Guidance on HBV Reactivation With Immunosuppressive Therapy

Clinical Thought
Rapid expansion of the use of new immunosuppressive agents and failure to screen patients for HBV prior to therapy initiation can lead to HBV reactivation. Here’s my approach to preventing reactivation.

Released: August 23, 2021

Expiration: August 22, 2022

No longer available for credit.

Share

Faculty

George K. K. Lau

George K. K. Lau, MD

Assistant Dean, Faculty of Medicine
The University of Hong Kong
Honorary Consultant
Gastroenterology and Hepatology
The Queen Mary Hospital
Hong Kong, China

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from:

Gilead Sciences, Inc.

Faculty Disclosure

Primary Author

George K. K. Lau, MD

Assistant Dean, Faculty of Medicine
The University of Hong Kong
Honorary Consultant
Gastroenterology and Hepatology
The Queen Mary Hospital
Hong Kong, China

George Lau, MD, has no relevant conflicts of interest to report.